Sign In
Buy ALRN
$2.11
+0 (+0%)
At Close: Apr 09, 2025
Analysts Offer Insights on Healthcare Companies: Tactile Systems Technology (NASDAQ: TCMD) and Aileron Therapeutics (NASDAQ: ALRN)
10:05am, Thursday, 23'rd Apr 2020
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Tactile Systems Technology (
TCMD
–
Research Report
) and Aileron Therapeutics (
ALRN
–
Research Re
Aileron Therapeutics Announces Plans to Release Interim Results from its Phase 1b/2 Myelopreservation Study in Mid-2020
12:30pm, Wednesday, 22'nd Apr 2020
Aileron Therapeutics (ALRN) today announced plans to report interim results from their Phase 1b/2 clinical trial of ALRN-6924 in small cell lung cancer (SCLC). In this trial, ALRN-6924 is being evalu
Aileron Therapeutics initiated with a Buy at JonesTrading ALRN
01:07pm, Wednesday, 08'th Apr 2020
Aileron Therapeutics initiated with a Buy at JonesTrading JonesTrading ALRN
JonesTrading Thinks Aileron Therapeutics' Stock is Going to Recover
12:38pm, Wednesday, 08'th Apr 2020
JonesTrading analyst Soumit Roy initiated coverage with a Buy rating on Aileron Therapeutics (ALRN) today and set a price target of $5.00. The company's
JonesTrading Thinks Aileron Therapeutics’ Stock is Going to Recover
12:38pm, Wednesday, 08'th Apr 2020
JonesTrading analyst
Soumit Roy
initiated coverage with a
Buy
rating on Aileron Therapeutics (
ALRN
–
Research Report
) today and set a price target of
$5.00
. The company’s shares closed last Tue
Canaccord Genuity Thinks Aileron Therapeutics' Stock is Going to Recover
10:12am, Friday, 03'rd Apr 2020
Aileron Therapeutics (ALRN) received a Buy rating and a $5.00 price target from Canaccord Genuity analyst John Newman yesterday. The company's shares
Canaccord Genuity Thinks Aileron Therapeutics’ Stock is Going to Recover
10:12am, Friday, 03'rd Apr 2020
Aileron Therapeutics (ALRN – Research Report) received a Buy rating and a $5.00 price target from Canaccord Genuity analyst John
Analysts' Top Healthcare Picks: Aileron Therapeutics (ALRN), Mersana Therapeutics (MRSN)
11:09am, Tuesday, 31'st Mar 2020
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aileron Therapeutics (ALRN) and Mersana Therapeutics (MRSN)
Analysts’ Top Healthcare Picks: Aileron Therapeutics (ALRN), Mersana Therapeutics (MRSN)
11:09am, Tuesday, 31'st Mar 2020
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aileron Therapeutics
Aileron Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
08:16pm, Monday, 30'th Mar 2020
Aileron Therapeutics (ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides, today reported business highlights and financial results for the fourth quarter and full ye
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) * Masimo Corporation (NASDAQ: MASI)Down In The Dum
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 12.)
Masimo...
The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO
11:37am, Thursday, 12'th Mar 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 11) * Bicycle Therapeutics PLC (NASDAQ: BCYC) (reacte
The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO
12:00am, Thursday, 12'th Mar 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on March 11)
Bicycle Therapeutics...
ReAlta Life Sciences Strengthens Board of Directors with Appointments of Industry Leaders Dr. Deborah Geraghty and Dr. Azmi Nabulsi
01:48pm, Tuesday, 10'th Mar 2020
ReAlta Life Sciences Strengthens Board of Directors with Appointments of Industry Leaders Dr. Deborah Geraghty and Dr. Azmi Nabulsi.
